migraines

Pfizer recalls migraine drug Nurtec ODT after millions of products lacked child resistant packaging
Pfizer recalls migraine drug Nurtec ODT after millions of products lacked child resistant packaging
USA Today
Pfizer
Nurtec ODT
migraines
packaging
product recalls
Flag link:
Royalty Pharma nabs $475M milestone from Pfizer upon migraine nasal spray OK
Royalty Pharma nabs $475M milestone from Pfizer upon migraine nasal spray OK
Endpoints
Pfizer
migraines
Royalty Pharma
Biohaven
zavegepant
Flag link:
Pfizer's Biohaven bet pays off again as migraine nasal spray wins approval
Pfizer's Biohaven bet pays off again as migraine nasal spray wins approval
BioSpace
Pfizer
Biohaven
FDA
migraines
nasal spray
zavegepant
Zavzpret
Flag link:
Pfizer cites positive results on nasal spray migraine treatment
Pfizer cites positive results on nasal spray migraine treatment
Medical Xpress
Pfizer
migraines
The Lancet
nasal spray
zavegepant
Flag link:
Satsuma in the red after 2nd phase 3 migraine flop spurs search for strategic alternatives
Satsuma in the red after 2nd phase 3 migraine flop spurs search for strategic alternatives
Fierce Biotech
Satsuma Pharmaceuticals
clinical trials
migraines
STS101
intra-nasal drug delivery
Flag link:
Eli Lilly ordered to pay $177M to rival Teva in migraine patent fight
Eli Lilly ordered to pay $177M to rival Teva in migraine patent fight
Fierce Pharma
Eli Lilly
legal
migraines
Ajovy
patents
Flag link:
With Pfizer sale in the rearview, Biohaven veers toward Kv7 platform following late-stage trial fails, delays
With Pfizer sale in the rearview, Biohaven veers toward Kv7 platform following late-stage trial fails, delays
Fierce Biotech
Pfizer
Biohaven
migraines
epilepsy
Flag link:
Satsuma peels off fresh strip of long-term migraine study data ahead of planned FDA filing
Satsuma peels off fresh strip of long-term migraine study data ahead of planned FDA filing
Fierce Pharma
Satsuma Pharmaceuticals
migraines
clinical trials
STS101
Flag link:
Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled
Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled
Fierce Pharma
Lundbeck
earnings
migraines
CGRPs
Vyepti
Flag link:
AbbVie files Qulipta for chronic migraine prevention
AbbVie files Qulipta for chronic migraine prevention
Pharmaforum
AbbVie
Qulipta
migraines
FDA
Flag link:
Zosano goes bankrupt after FDA rejects migraine drug delivery patch
Zosano goes bankrupt after FDA rejects migraine drug delivery patch
Fierce Pharma
Zosano Pharma
migraines
FDA
bankruptcy
Flag link:
After filing for bankruptcy, rejected migraine drug developer Zosano’s value more than halved
After filing for bankruptcy, rejected migraine drug developer Zosano’s value more than halved
Endpoints
Zosano Pharma
migraines
layoffs
FDA
Flag link:
Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs
Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs
BioPharma Dive
Pfizer
M&A
Biohaven
migraines
Flag link:
No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program
No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program
Fierce Pharma
Zosano Pharma
FDA
migraines
migraine patch
M207
Flag link:
As expected, FDA spikes down Axsome migraine med, but issues are 'addressable'
As expected, FDA spikes down Axsome migraine med, but issues are 'addressable'
Fierce Biotech
Axsome Therapeutics
migraines
FDA
AXS-07
Flag link:
It's CRL Day at the FDA as Axsome, Junshi and Coherus Get Bad News
It's CRL Day at the FDA as Axsome, Junshi and Coherus Get Bad News
BioSpace
FDA
complete response letter
Junshi Biosciences
Coherus Biosciences
Axsome Therapeutics
migraines
AXS-07
Flag link:
After culling workforce, migraine biotech Zosano drops lead — and sole — program
After culling workforce, migraine biotech Zosano drops lead — and sole — program
Endpoints
Zosano
migraines
layoffs
M207
Flag link:
Biohaven migraine drug partnered with Pfizer lands twin European approvals
Biohaven migraine drug partnered with Pfizer lands twin European approvals
MedCity News
Europe
Pfizer
Biohaven
migraines
rimegepant
Flag link:
Axsome expects migraine drug to be rejected as manufacturing issues arise
Axsome expects migraine drug to be rejected as manufacturing issues arise
Endpoints
Axsome Therapeutics
migraines
FDA
AXS-07
Flag link:
Zosano's headaches continue: Biotech lays off 31% after FDA rejects migraine drug resubmission
Zosano's headaches continue: Biotech lays off 31% after FDA rejects migraine drug resubmission
Fierce Biotech
Zosano Pharma
layoffs
migraines
M207
Flag link:

Pages